Citraglucosolan (Powder) Instructions for Use

ATC Code

A07CA (Oral rehydrating salt preparations)

Clinical-Pharmacological Group

Drug for rehydration and detoxification for oral use

Pharmacotherapeutic Group

Rehydrating agent for oral administration

Indications

• Oral rehydration therapy for adults and children with acute diarrhea of any etiology, accompanied by mild to moderate dehydration (fluid loss of 3-9% of body weight).
• Correction and prevention of water-electrolyte imbalances and acidosis in conditions associated with significant fluid loss (e.g., intense physical exertion, heat stress).
• Detoxification therapy as part of complex treatment for various intoxications to accelerate the elimination of toxic substances from the body.

Contraindications

• Hypersensitivity to any component of the drug.
• Severe renal impairment (anuria, oliguria) due to the risk of hyperkalemia and hypernatremia.
• Uncontrollable vomiting that prevents oral administration and retention of the solution in the gastrointestinal tract.
• Severe dehydration (fluid loss >9-10% of body weight, signs of hypovolemic shock), requiring immediate intravenous rehydration.
• Hyperkalemia of any etiology, as the preparation contains potassium chloride.
• Intestinal obstruction and conditions with a high risk of its development, as increased fluid intake may exacerbate the condition.
• Impaired consciousness or coma, due to the high risk of aspiration during oral administration.

Dosage Regimen

The dosage of Citraglucosolan is individualized based on the patient’s age, body weight, and the degree of dehydration. The contents of one sachet must be dissolved in 1 liter of freshly boiled and cooled drinking water. The prepared solution should be used within 24 hours, stored in a refrigerator.

For acute diarrhea in adults, the average dose is 50-100 ml/kg body weight over the first 4-6 hours, followed by maintenance therapy at a dose of 80-100 ml/kg body weight until diarrhea ceases. The solution should be taken in small sips after each loose stool.

For children, the dosage is calculated based on body weight: for mild dehydration – 30-50 ml/kg over 4 hours; for moderate dehydration – 50-100 ml/kg over 4-6 hours. For infants, the solution can be given from a spoon or bottle. It is recommended to continue breastfeeding or formula feeding during rehydration therapy.

For the prevention of dehydration during intense physical exertion or in hot climates, the solution is taken in small portions throughout the day, with the total volume not exceeding 2 liters for adults. The duration of treatment is determined by the doctor, usually not exceeding 3-4 days for acute diarrhea.

Adverse Reactions

When used as directed, adverse reactions are rare. From the gastrointestinal tract: possible nausea, vomiting (usually with too rapid administration of the solution). These phenomena are usually transient and do not require discontinuation of therapy.

In patients with impaired renal function, with prolonged use or exceeding recommended doses, symptoms of hyperkalemia (muscle weakness, cardiac arrhythmias) or hypernatremia (thirst, oliguria, peripheral edema) may develop. Allergic reactions (skin rash, itching, urticaria) are possible in case of individual hypersensitivity to the components of the drug.

If any adverse reactions occur, it is recommended to temporarily stop taking the drug and consult a doctor for correction of therapy.

Drug Interactions

Due to the potassium content, simultaneous use with potassium-sparing diuretics (spironolactone, triamterene, amiloride), ACE inhibitors, angiotensin II receptor antagonists, cyclosporine, tacrolimus may increase the risk of hyperkalemia, requiring monitoring of potassium levels in the blood plasma.

Concomitant use with glucocorticosteroids may contribute to sodium and fluid retention in the body. The solution may affect the absorption of other oral medications, so it is recommended to maintain an interval of 1-2 hours between taking Citraglucosolan and other drugs.

When used simultaneously with cardiac glycosides, hyperkalemia may increase their toxic effect. In case of simultaneous use with drugs that affect electrolyte balance, regular monitoring of plasma electrolyte levels is necessary.

Overdose

In case of overdose, symptoms of hypernatremia (thirst, oliguria, tachycardia, arterial hypertension, agitation, confusion, in severe cases – convulsions, coma) and hyperkalemia (muscle weakness, paresthesia, bradycardia, cardiac conduction disturbances, cardiac arrest) may develop.

Treatment: immediate discontinuation of the drug, correction of water-electrolyte imbalances under medical supervision. In case of severe hyperkalemia, intravenous administration of calcium gluconate, glucose with insulin, sodium bicarbonate is indicated; in case of hypernatremia – administration of salt-free solutions (5% glucose solution) under the control of plasma sodium levels. In severe cases, hemodialysis may be required.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.